Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The German Network for Personalized Medicine to enhance patient care and translational research

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1


  1. Fioretos, T. et al. Nat. Med. 28, 1980–1982 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Taskén, K. et al. Nat. Med. 28, 885–887 (2022).

    Article  PubMed  Google Scholar 

  3. Renovanz, M. et al. Neuroncol. Adv. (2023).

    Article  Google Scholar 

  4. Joos, S. et al. Mol. Oncol. 13, 535–542 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Horak, P. et al. Cancer Discov. 11, 2780–2795 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Saiyed, M. M., Ong, P. S. & Chew, L. J. Clin. Pharm. Ther. 42, 251–258 (2017).

    Article  CAS  PubMed  Google Scholar 

  7. Schett, G., McInnes, I. B. & Neurath, M. F. N. Engl. J. Med. 385, 628–639 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Stenzinger, A. et al. Semin Cancer Biol. 84, 242–254 (2022).

    Article  PubMed  Google Scholar 

  9. Vicente, A. M., Ballensiefen, W. & Jönsson, J. I. J. Transl. Med. 18, 180 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to N. P. Malek.

Ethics declarations

Competing interests

A.L.I. received honoraria for consulting and advisory boards from Janssen-Cilag, AbbVie, Roche, AstraZeneca, Amgen and Takeda. A.S. has received honoraria for consulting and/or advisory boards from Agilent, Aignostics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Takeda, and Thermo Fisher; and grants from Bayer, BMS, Chugai, and Incyte. M.B. received honoraria for advisory boards from Roche, Incyte Biosciences Germany, Bayer Vital, BMS, MSD Sharp & Dome, Taiho Oncology Europe, and EISAI. V.I.G. is on the advisory board for Jazz Pharmaceuticals and Abbvie; received speakers bureau fees for Pfizer, Janssen, and Abbvie; and travel support from Abbvie. S.L. reports research grant from BMS, advisory board/speaker invitation from AstraZeneca, Eli Lily, Roche, and Takeda outside of this work. S.O. received honoraria for workshop presentations at conferences from Illumina. M.H. received honoraria for lectures, presentations, speakers bureaus and consulting advisory boards from Abbvie, Roche, AstraZeneca, Gilead, Janssen, and Beigene. P.A. received fees from Ferring Pharmaceuticals and Bayer. T.F. received honoraria from Onkowissen. P.B. received honoraria for consulting and advisory boards from Bristol Myers Squibb, AstraZeneca, Amgen, and MSD. D.S. has been on the advisory board, an invited speaker, or committee member for BMS, Immunocore, Merck Serono, MSD, Neracare, Novartis, Pfizer, Philogen, Pierre Fabre, Roche, Sanofi, and Regeneron; received research grants from or been principal investigator for BMS, MSD, Novartis, Philogen, Pierre Fabre, and Sanofi; and is a member of the board of directors for EORTC-MG. A.B. received honoraria for consulting and advisory boards from MSD, Boehringer Ingelheim, Takeda, AstraZeneca, BMS, Lilly, Roche Pharma, Pfizer, Sanofi, Janssen-Cilag, Bayer Vital, Amgen, Novartis, and Daiichi Sankyo. C.H.B. received honoraria for consulting and advisory boards from MSD, BMS and Novartis. I.E. received consulting fees from Incyte Bioscience International. E.M. received speaker honoraria from Roche and Boehringer Ingelheim; and is on an advisory board for Roche. C.B. has been on the advisory board, an invited speaker, or committee member for AOK Germany, AstraZeneca, Bayer Healthcare, BioNTech, Bristol Myers Squipp, Jansen Cilag, Med Update, Merck Serono, Oncology Drug Consult CRO, Roche Pharma, and Sanofi Aventis; several clinical trials sponsored by industry; member of board of directors for DGHO and Northern German Society of Internal Medicine; leadership roles at Hamburg Cancer Society and National Network of German Cancer Centers (DKH); and advisory role at board of DGHO advisors. S.F. received consulting fees or advisory board membership from Bayer, Illumina, and Roche; honoraria from Amgen, Eli Lilly, PharmaMar, and Roche; research funding from AstraZeneca, Pfizer, PharmaMar, and Roche; and travel or accommodation expenses from Amgen, Eli Lilly, Illumina, PharmaMar, and Roche. H.A. received honoraria for consulting and advisory boards from AstraZeneca, Viatris, Pfizer, and Servier. V.H. declares honoraria for talks and advisory board roles from Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Celgene, Terumo, Oncosil, Seagen, and NORDIC Pharma; and research funding from Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, SIRTEX, and Servier. R.B. is patent holder for blinatumomab, from which he receives royalty payments, and has consulted for and received honoraria from Amgen, Cellex, and Gemoab. P.H. received honoraria from MSD and AstraZeneca. F.L. received honoraria from Astellas, AstraZeneca, BMS, MSD, and Roche. A.H. received research support from Novartis, BMS, Pfizer, and Incyte. M.T. received honoraria for consulting or advisory boards from Janssen-Cilag, Roche, AstraZeneca, Amgen, Takeda, BMS, IO Medico, Sana, RKH Kliniken, ConEvent, Med Update, VHS Stadtbergen, I-Med Institut, and Klinikum Esslingen. J.B. received honoraria from MSD. M.W. reports research grant from BMS outside of this work. A.J.B. received honoraria for talks, consulting, or advisory boards from Siemens Healthineers, NVision, and AAA/Novartis. G.T. has served on advisory boards for Bayer, Boehringer Ingelheim, CureVac, and Novocure, consulted for Bayer, Boehringer Ingelheim, and CureVac; was a steering committee member in non-interventional trials for Bayer and Novocure; with financial compensation for all these activities provided as institutional funding to the University Hospital Tübingen. W.W. received research grants from Roche, MSD, BMS, and AstraZeneca; advisory board, lectures, speaker bureaus fees from Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Janssen, Amgen, Astellas, Illumina, Eisai, Siemens, Agilent, ADC, GSK, and Molecular Health. U.K. received research support from AstraZeneca; and honoraria from BMS, MSD, Merck, and Novartis. T.S. received honoraria for consulting of editorial boards for Servier, M&D, BMS, Mirati, Olympus Fondation Pierre Fabre, and Eli Lilly. P.S. received honoraria from speakers bureau or advisory boards for Incyte, BMS, Eisai, MSD, AstraZeneca, and Amgen; and from BMS, Gilead, Incyte, and Huygai. All other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Illert, A.L., Stenzinger, A., Bitzer, M. et al. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med 29, 1298–1301 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing